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ABSTRACT 
Background: The atrial natriuretic peptide (ANP) 
regulates fluid volume redistribution between heart 
and the pulmonary vessels. In diabetic patients the 
physiological action of ANP appears to be seriously 
altered. Methods: 12 subjects (gender 6M/6F, age 47 ± 
2 years, BMI 29.1 ± 0.1 kg/m2), with type 2 diabetes 
and under stable conditions, were studied after one 
month of pioglitazione treatment (30 mg/die) by 
means of isotonic blood volume expansion. Results: 
After one month of pioglitazone treatment the meta- 
bolic profile of the subjects improved (decrease dia- 
stolic blood pressure: p = 0.05, total cholesterol: p = 
0.01, triglycerides: p = 0.03 and blood glucose: p = 
0.01) as the expansion of their plasma volume was 
found associated with the decrease of hematocrit (p < 
0.05). The statistical comparison before versus after 
pioglitazone showed a significant decrease in the ba- 
sal aldosterone levels post-treatment (p < 0.04). None-
theless ANP plasma levels were similar before and 
after therapy. Conclusions: The inappropriately high 
concentrations of ANP induced by hyperglycemia 
and the abnormal responses to a physiological sti- 
mulus like an isotonic blood volume expansion are 
not reverted by one month of pioglitazone. This is in 
contrast with the brisk improvement of the meta-
bolic profile seen for the same period of treatment. 
ANP secretion is modified by fluid load in diabetic 
patients. This anomaly is not reverted by pioglita-
zone. 
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1. INTRODUCTION 
The Atrial Natriuretic Peptide (ANP) is a hormone play- 
ing a major role in fluid homeostasis by protecting the 
cardiovascular system against volume overload. This 
polypeptide is released by the myocardium into the cir- 
culation in response to atrial distension. ANP release is 
enhanced during hypertonic saline infusion followed by 
spontaneous water drinking, due to the increase of atrial 
pressure [1] and as a consequence of the atrial stretch 
during an expansion of the intravascular fluid compart- 
ment [2,3]. Acute infusion of insulin [3,4], glucose load 
[5], and hyperglycemia [6] are able to increase the 
plasma levels of ANP. The infusion of physiological 
doses of ANP does not modify renal extraction nor cause 
vasodilatation, although it elicits an increase in capillary 
filtration [7]. 
In heart transplant recipients high levels of ANP were 
found after surgery [8,9], thereafter normalized to phy- 
siological levels [10] or, according to some other reports 
[11], remained persistently high values. We previously 
showed that diabetic heart transplanted patients, had 
elevated plasma ANP concentrations similarly to the not 
transplanted diabetic patients. In contrast, non diabetic 
patients had normal plasma ANP levels. Therefore, chro- 
nic hyperglycemia seemed to be the main factor respon- 
sible of the increase of ANP concentration [12]. 
Type 2 diabetes itself is a pathologic condition char- 
acterized by volumetric expansion, associated with al- 
teration of sympathetic system as well as peripheral neuro- 
pathy [13]. As a consequence of this, in type 2 diabetic 
patients (T2DP), alterations of cardio-pulmonary affer-
ences [14], and of renin-angiotensin axis [15] along with 
irregular secretion of atrial natriuretic peptide [16,17] 
were described, underlying a possible decrease of den-
sity and sensibility of peripheral receptors [18]. 
The sodium retention effect of thiazolidinediones (TZD) 
is very relevant in T2DP.. 
In isolated myocytes TZD was able to decrease the 
secretion of ANP [19,20]. Nonetheless, it is currently not 
clear whether TZD have a direct effect on endocrine me- 
chanisms regulating the water-salt balance in humans. *Corresponding author. 
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Pioglitazone is a thiazolidinedione compound that acts 
as a peroxisome proliferator activating receptor (PPAR)- 
γ agonist with potential benefits on insulin resistance. 
Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] 
phenyl] methyl]-2,4-] thiazolidinedione monohydrochlo- 
ride contains one asymmetric carbon, and the compound 
is synthesized and used as the racemic mixture. This 
drug is an antihyperglycaemic agent that, in the patients 
with insulin resistance, increases hepatic and peripheral 
insulin sensitivity, due to inhibition of hepatic gluconeo- 
genesis and to increase peripheral and splanchnic glu-
cose uptake [21]. 
The present work was undertaken to assess the effect 
of one month of pioglitazone treatment on plasma ANP 
concentration and the related metabolic profile in this 
cohort of diabetic individuals. 
Considering the effects of pioglitazone on plasma renin 
activity and plasma aldosterone, the ability of PPAR γ 
agonists to increase renal sodium reabsorption is most 
likely due to the activation of the renin-aldosterone system. 
Moreover, pioglitazone was proved to have a significant 
effect on renin secretion and renal sodium handling 
which may contribute to the development of peripheral 
edema in some patients [22,23]. The present study aimed 
at investigating a putative dissociation between a short- 
term pioglitazone treatment and fluid homeostasis in 
T2DP. 
2. MATERIALS AND METHODS 
2.1. Subjects 
Twelve subjects affected by type 2 diabetes mellitus (6 
men/6 women, caucasians, age 47 ± 2 years, duration of 
diabetes 8 ± 2 years, weight 64.2 ± 2.5 Kg, BMI 29.1 ± 
0.1 Kg/m2) under stable conditions in the previous 6 
months, were selected for this study among the popula- 
tion of patients treated at the Endocrinology Unit of 
Ospedale L. Sacco in Milan (Italy). A medical history, 
physical examination, and biochemical laboratory screen- 
ing tests were obtained to exclude patients with major 
gastrointestinal, cardiovascular, neuralgic or infectious 
disorders. All patients were on oral hypoglycemic agent. 
The subjects were instructed on the purpose, benefits 
and risks of the study and gave their written consent in 
accordance with protocols approved by the Institutional 
Ethical Committee. 
2.2. Experimental Protocol 
In the two weeks preceding the study all the subjects 
assumed an isocaloric diet containing at least 250 g of 
carbohydrates and 70 - 90 g of proteins per day. On day 
1, the patients were admitted to hospital at 5 pm for the 
isotonic saline infusion (2000 cc of NaCl 0.9% for 2 
hours). A teflon catheter was inserted into an antecubital 
vein for blood sampling and samples were obtained for 
blood cell count, renin, aldosterone, vasopressin, ANP, 
epinephrine and norepinephrine, concentrations, at base- 
line and during sampling at 30 min intervals up to 120 
min (basal, 30, 60, 90, 120 minutes). A basal fasting 
blood sample for lipid profile (apo-A1, apo-B total, and 
uric acid) and blood glucose was drawn before starting 
the infusion. After blood pressure and heart rate were 
measured at 60 and 120 min after starting the saline infu- 
sion. On day 2, after one month of pioglitazone treat-
ment (30 mg/day) the patients have undergone the same 
procedure of day 1. 
2.3. Analytical Methods 
All blood samples were placed on ice until plasma or 
serum was separated by centrifugation at 4˚C (within 1.5 
hours from sampling). All plasma and serum aliquots 
were frozen at −60˚C until later analysis. Aliquots of 
blood for measurement of ANP were collected in tubes 
containing EDTA plus Trasylol; all the samples were 
kept in ice and the plasma prepared by centrifugation at 
4˚C, within 1.5 hours from sampling. Plasma ANP was 
assessed by a specific Radio Immuno Assay with kits 
supplied by Nichols (Nichols Institute Diagnostic, Ca, 
USA). The plasma osmolality was determined with the 
freezing point depression method (Fiske osmometer by 
Fiske Co., Burlington, Ma, USA). Plasma glucose was 
measured with a Beckman glucose analyzer (glucose 
oxidase). 
The uric acid clearance (ClUr) is a good circulating 
marker of extracellular fluid; this marker increases in 
case of a water overload [24,25]. To calculate the uri-
nary clearance of uric acid, we used the equation: 
ClUr = [Ur(u)]/[Ur(s)] × Urinary volume 24 h/1440 
where Ur(u) is the urinary uric acid concentration and 
Ur(s) is the seric uric acid concentration. 
The variation of plasma volume (ΔVol) was calcu-
lated by using the value of hemoglobin (Hb) and Hema-
tocrit (Ht) according to the following equation: 
ΔVol = {(Hb1/Hb2) × [(100-Ht2)/(100-Ht1)] – 1} × 100 
Renin, aldosterone, vasopressin were measured by com- 
mercial Radio Immuno Assay kits. Epinephrine and Nore- 
pinephrine were measured by HPLC as previously de-
scribed [12]. Standard laboratory methods were used to 
assess blood cell count. Total cholesterol and triglyc- 
erides were determined in serum using manual enzy-
matic methods (Boehringer AG, Marburg, Germany). At 
the same time, high-density lipoprotein (HDL) choles-
terol was determined enzymatically after precipitation of 
apolipoprotein B (ApoB) with dextran sulfate. Low-den-
sity lipoprotein (LDL) cholesterol was calculated ac-
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cording to Friedewald’s equation. ApoB and ApoA1 
were measured at weeks 0, 8, and 20 from the beginning 
of the treatment, using commercially available radio-im- 
muno-diffusion methods. 
2.4. Statistical Analysis 
Data are expressed as means ± SE. Comparison between 
before and after one month of pioglitazone treatment were 
performed with the Student’s t test for paired data (a p-value 
less than 0.05 was considered statistically significant). 
3. RESULTS 
No adverse events were observed during administration 
of pioglitazone. Clinical, anthropometrics and laboratory 
data are summarized in Table 1. No statistical difference 
was evident for any anthropometric data after one month 
of therapy. In contrast, diastolic blood pressure was lower 
after one month pioglitazone treatment. 
Our study confirmed the decrease of total cholesterol, 
Apo B and triglycerides levels after one month treatment 
with pioglitazone. 
Plasma volume expansion was also confirmed and out- 
lined by the significant reduction of hematocrit (p < 0.05 
with respect to pre-treatment period). 
Volume expansion was similar in the basal condition 
at the baseline and after therapy as indicated after 120 
minutes from the infusion of 2 liter of 0.9% NaCl solu-
tion. Table 2 shows hormone responses to test volume 
expansion before and after therapy. Plasma volume ex-
pansion after therapy with pioglitazone induced a de-
crease of plasma aldosterone during infusion of 2 liter of 
0.9% NaCl solution (p < 0.05 at 60’, 90’, 120’ vs basal). 
The decrease of vasopressin and renin plasma was evi-
dent about before therapy after volume expansion (at 30’, 
60’, 90’, 120’) and the decrease after therapy was pre-
sent only at the end of study (90’ and 120’). 
In the pre treatment condition, during saline infusion, 
we observed a trend to decrease of plasma norepineph-
rine and epinephrine (Table 3). 
In contrast, ANP concentration resulted to be signifi-
cantly increased with respect to the basal condition, after 
2 hours of saline infusion test (Figure 1). 
After one month treatment with pioglitazone we de-
tected a significant decrease of aldosterone at each time 
point during the isotonic test (p < 0.04 vs pre-treatment 
values), whereas ANP plasma levels were similar to the 
prior treatment condition regardless of therapy (p = ns). 
Epinephrine and norepinephine did not decrease after 
two hours of saline infusion after therapy with pioglita-
zone (Table 3). After 120 minutes of saline infusion 
both epinephrine and norepinephine showed higher lev-
els in comparison with the prior condition. 
Table 1. Clinical and laboratory characteristics of study sub-
jects before and after therapy with pioglitazone. 
 PRE pioglitazone POST pioglitazone
BMI (kg/m2) 29.15  0.89 29.09  0.86 
Waist (cm) 104.7  2.8 104.3  2.7 
Blood glucose (mmol/l) 8.55 0.19 7.51 0.13* 
Systolic blood  
pressure (mmHg) 127.5  3.6 124.0  1.9 
Diastolic blood  
pressure (mmHg) 81.5  2.4 77.0  1.7* 
Heart rate (bpm) 72  1.3 70.4  2.3 
Uric acid clearance 
(ml/min) 6.32  1.63 8.77  1.57* 
Hct (%) 40.13  0.97 38.39  1.14* 
Total Cholesterol  
(mmol/l) 4.62  0.20 4.30  0.18* 
HDL-C (mmol/l) 1.29  0.08 1.29  0.07 
LDL-C (mmol/l) 2.50  0.20 2.39  0.20 
Triglycerides (mmol/l) 1.79  0.34 1.34  0.20* 
Apo A1 (mg/dl) 117.5  4.5 116.0  4.6 
Apo B (mg/dl) 95.7  5.1 88.1  5.3* 
*p ≤ 0.05 vs pre. 
Table 2. Plasma renin activity, plasmatic aldosterone, plas-
matic vasopressin during volume expansion before and after 
therapy. 
Plasma renin  
activity (ng/l/s) PRE pioglitazone POST pioglitazone
t + 0 1.05  0.34 0.84  0.39 
t + 30 0.86  0.35 0.77  0.30 
t + 60 0.79  0.36 0.72  0.25 
t + 90 0.74  0.31 0.66  0.24 
t + 120 0.58  0.24 0.66  0.24 
Plasma aldosterone 
(pmol/l) PRE pioglitazone POST pioglitazone
t + 0 1600  262 1029  216 
t + 30 988  119 707  97* 
t + 60 705  63 560  59* 
t + 90 571  48 491  45* 
t + 120 504  36 460  29* 
Plasma vasopressin 
(pmol/l) PRE pioglitazone POST pioglitazone
t + 0 1.11  0.11 0.93  0.09 
t + 30 0.88  0.05 0.89  0.05 
t + 60 0.82  0.06 0.85  0.07 
t + 90 0.79  0.05 0.78  0.05 
t + 120 0.78  0.05 0.77  0.06 
*p < 0.05 vs pre; p < 0.05 vs t + 0. 
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Table 3. Plasma cathecolamins during volume expansion be- 
fore and after therapy. 
Plasma epinephrine  
(pg/ml) PRE pioglitazone 
POST pioglita-
zone 
t + 0 129.4  21.3 163.7  27.9 
t + 30 90.1  3.6 116.2  38.7 
t + 60 86.2  3.8 129.9  32.5 
t + 90 105  3.7 123.3  35.9 
t + 120 90.6  19.1 159.9  26.2* 
Plasma norepinephrine  
(nmol/l) PRE pioglitazone 
POST pioglita-
zone 
t + 0 0.14  0.02 0.18  0.3 
t + 30 0.10  0.01 0.13  0.2 
t + 60 0.09  0.02 0.14  0.4 
t + 90 0.11  0.02 0.13  0.4 
t + 120 0.10  0.2 0.17  0.3* 
*p < 0.05 vs pre 
 
 
Figure 1. Increase of atrial natriuretic peptide during volume 
expansion before and after pioglitazone treatment in diabetic 
patients. 
4. DISCUSSION 
In the present work we studied the circulating ANP re- 
sponses to an isotonic blood volume expansion after one 
month of pioglitazone therapy in 12 T2DP. Data from 
recent large-scale clinical trials [26] raised particular con- 
cerns in regard to the use of thiazolidinediones that ap-
pear to increase the risk of heart failure in T2DP. None-
theless and particularly, pioglitazone therapy has also 
been associated with a significantly lower risk of sudden 
death, myocardial infarction, or stroke among different 
populations of patients with diabetes as indicated by a 
recent meta-analysis [27]. It was also verified that, in 
large clinical studies, the occurrence of edema with thia- 
zolidinediones was not associated with an increase in 
heart failure events [28]. 
The use of thiazolidinediones can be very useful in the 
treatment of type 2 diabetes mellitus and particularly by 
decreasing cardiovascular risk [29-32]. Therefore the 
significant sodium retention in a subpopulation of pa- 
tients with serious alteration of salt/water homeostasis 
could be an important limitation as to the use of this 
class of drugs. 
In our study the reduction of hematocrit and relative 
dilution of blood cell counts after one month of pioglita- 
zone treatment seem to support the sodium retention in- 
duced by TZD. 
The ANP plasma level is an important marker to iden- 
tify patients at high risk for of heart failure and, in gen- 
eral, other natriuretic peptides (like the amino terminus 
of Atrial Natriuretic Peptide, the Brain Natriuretic Pep- 
tide, and the amino terminus of Brain Natriuretic Peptide) 
were even better markers for two and three-year follow- 
up outcome in mild and moderate chronic heart failure- 
patients [20,33]. 
In humans, the physiological ANP secretion by myo- 
cardiocytes of the right atrium is regulated by a variation 
of the venous return and consequently by a change of the 
intra-atrial pressure. Only partially ANP secretion is re- 
gulated by plasma osmolality [34]. 
We recently demonstrated that after acute insulin sti- 
mulation, the plasma concentration of ANP increased 
similarly in four groups: T2DP patients (without heart 
transplantation as control), healthy subjects as controls, 
and in diabetic and nondiabetic heart-transplanted pa- 
tients; the four groups of subjects investigated were ho- 
mogenous for age, similar time elapsed from transplant, 
good general conditions, and normal hemodynamic pro- 
files. No differences parameters were also noted for plas- 
ma catecholamine concentration and osmolality [12]. There- 
fore the presence of chronic hyperglycemia emerged as 
the major factor responsible for the higher plasma ANP 
concentrations measured in transplant recipients with 
glucose intolerance or overt diabetes. 
The present results show that subjects with diabetes 
prior or after pioglitazone therapy have the similar re- 
sponse of ANP plasma concentration to volume expan- 
sion. These patients, after therapy, have expanded the 
circulating volume, as demonstrated by the hematocrit 
decrease and by plasma aldosterone levels. 
Interestingly similar basal and after saline infusion 
ANP plasma levels were ascertained before and after the 
pioglitazone therapy, independently of the expanded 
volume triggered by the treatment. The present results 
have a strong clinical impact: 1) It is clear that ANP 
concentration could not be used as a marker of subclini- 
cal heart failure in diabetic patients treated or not with 
pioglitazone; 2) Type 2 diabetic patients even if in stable 
metabolic conditions have a severe alteration of ANP 
secretion/degradation in response to a physiological sti- 
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mulus (circulating volume expansion), independently of 
sympathetic innervation; 3) Such impaired ANP plasma 
level regulation in type 2 diabetes is not reverted by one 
month of pioglitazone therapy, even if the metabolic and 
clinical profile is significantly improved (i.e. lipid-, glu- 
cose profile, and blood pressure). 
The alteration of ANP plasma concentration during 
diabetes mellitus has not an univocal explanation. First, 
heart denervation or partial reinnervation may not have a 
role in the regulation of ANP balance [8,9]. Therefore a 
partial defect of sympathetic system is not relevant in the 
regulation of ANP plasma concentration, while chronic 
hyperglycemia (in type 2 diabetic patients with and with- 
out transplantation) induces elevated levels of plasma 
ANP levels regardless of chronic hyperinsulinemia. Sec- 
ond, Zanchi and colleagues [23] showed in healthy sub- 
jects no changes in ANP values with pioglitazone treat- 
ment and the authors suggested a certain degree of pe- 
ripheral vasodilatation along with volume redistribution 
as possible causes of fluid retention rather than ANP. 
Third, studies in animal models showed that treatment 
with a TZD (rosiglitazone) induced cardiac hypertrophy 
in both cardiomyocyte-specific PPAR-knockout mice and 
in the littermate controls. These transgenic mice were 
found to have increased expression of cardiac embryonic 
genes (atrial natriuretic peptide) [20]. Sechi and col- 
leagues pointed out that the decreased number of bio- 
logically active ANP receptors in the kidneys of diabetic 
rats is coupled to an overall decreased biological respon- 
siveness in vitro, and that provides a potential explana-
tion for the reduction in renal sensitivity to ANP in the 
diabetic condition [18]. 
Our data seem to be in contrast with results found in a 
recent publication [35] showing that in type 2 diabetic 
subjects the impairment of ANP response to immersion 
was restored by rosiglitazone (after they had taken 4 mg 
of rosiglitazone every morning for 7 days prior to the 
study). However, the different type of TZD and the par- 
ticular stimulus to cause volume expansion head-out wa- 
ter immersion) could explain the differences found in 
that study. 
Since the increased levels of plasma ANP concentra- 
tions represent a noted predictor of worsening of the car- 
diac pump failure in patients with diabetes, our results 
suggest that ANP may be involved in the pathogenesis 
of cardiomyopathy and heart failure in diabetic recipi-
ents during TZD treatment. In conclusion, plasma ANP 
response to plasma volume expansion is completely al-
tered in T2DP and one month of pioglitazone therapy is 
not able to revert this condition. 
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